Journal
EXPERT REVIEW OF ANTICANCER THERAPY
Volume 7, Issue 12, Pages 1717-1727Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/14737140.7.12.1717
Keywords
apoptosis; marker panel; multimarker analysis; p53; protein expression; retinoblastoma; urothelial carcinoma
Categories
Funding
- NCI NIH HHS [CA-103455, CA-14089, CA-70903, CA-86871, CA-71921] Funding Source: Medline
Ask authors/readers for more resources
Bladder cancer is the seventh most common malignancy worldwide, with almost 14,000 patients dying from this disease in the USA alone. Because of the need for long-term and frequent follow-up, as well as the paucity of sensitive and specific noninvasive tests, bladder cancer management has the highest cost per patient among all cancer types. Several molecular markers, especially members of the cell cycle regulation and apoptosis pathways, have been investigated. However, no individual marker has been prognostically powerful enough to change clinical management. The combined analysis of a panel of markers spanning different pathways is the most promising approach. We give an overview of the most important molecular markers functioning in crucial pathways and focus on their role in multimarker analysis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available